Antiviral Remdesivir
Click on image to review CME course
Click on reference to access original papers.
Oct.2020 New England Journal of Medicine Remdesivir for the Treatment of Covid-19 — Final Report
1062 patients, double blind, randomized, placebo controlled.
Results
- Recovery 10 days in treatment group vs 15 in placebo group
- Mortality 6.7% in treatment group vs 11% in placebo group
Conclusion:
“This double-blind, randomized, placebo-controlled trial identified an antiviral therapy as beneficial in the treatment of Covid-19.”
October 2020 WHO Solidarity Trial
405 hospitals. 30 countries, 11,266 patients, no placebo controls
Randomized to 4 different treatment groups and one control group
Results
No difference in treatment and control arms
- Hospitalization time
- Mortality
Problems
- Large variation of treatment process between 30 hospitals
- Large variation in quality of care between 30 hospitals
- No consistent treatment start time in progression of disease
- At what point in disease progression did treatment begin
July 2020 Gilead Press Release Phase 3 Trial Data
- 60% reduction mortality
- FDA emergency authorization in effect
- Hospitalized patients
- Severe disease
- Pediatric effective
- Pregnant and post-partum
